ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN

ANGIOTENSIN II RECEPTOR ANTAGONISTS AND NEPHROPROTECTION: PLACE OF OLMESARTAN

The paper presents the results of experimental studies and clinical trials which demonstrate nephroprotective effects of olmesartan.

Saved in:

Bibliographic Details
Main Author:	V. V. Fomin
Format:	Article
Language:	Russian
Published:	«SILICEA-POLIGRAF» LLC 2013-08-01
Series:	Кардиоваскулярная терапия и профилактика
Subjects:	arterial hypertension diabetes mellitus nephroprotection olmesartan
Online Access:	https://cardiovascular.elpub.ru/jour/article/view/219
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Difficult choice: angiotensin receptor antagonists
by: E. O. Taratukhin
Published: (2013-04-01)

Up-to-Date Aspects of Antihypertensive Therapy from the Viewpoint of Cardioand Nephroprotective Action: Olmesartan
by: A. G. Evdokimova, et al.
Published: (2020-05-01)

ANGIOTENSIN RECEPTOR ANTAGONISTS: GOING WITH THE TIMES
by: E. O. Taratukhin
Published: (2013-06-01)

Carotid intima-media thickness and plaque volume changes following 2-year angiotensin II-receptor blockade. The Multicentre Olmesartan atherosclerosis Regression Evaluation (MORE) study
by: Kl. O. Stumpe, et al.
Published: (1970-01-01)

EFFECT OF ANGIOTENSIN RECEPTOR BLOCKADE ON ENDOTHELIAL FUNCTION: FOCUS ON OLMESARTAN MEDOXOMIL
by: C. Ferrario
Published: (2010-12-01)

ENDOTHELIAL-TROPIC AND NEPHROPROTECTIVE EFFECTS OF COMBINED ANTIHYPERTENSIVE THERAPY IN PATIENTS WITH TYPE 2 DIABETES MELLITUS
by: M. E. Statsenko, et al.
Published: (2015-09-01)

ANTIHYPERTENSIVE EFFICACY OF OLMESARTAN MEDOXOMIL, A NEW ANGIOTENSIN II RECEPTOR ANTAGONIST, AS ASSESSED BY AMBULATORY BLOOD PRESSURE MEASUREMENTS
by: J. M. Neutel, et al.
Published: (2011-04-01)

Metabolic syndrome and angiotensin II receptor antagonists
by: K. M. Mamyrbayeva, et al.
Published: (2007-04-01)

LONG-TERM EFFECTS OF OLMESARTAN, AN ANG II RECEPTOR ANTAGONIST, ON BLOOD PRESSURE AND THE RENIN-ANGIOTENSIN-ALDOSTERONE SYSTEM IN HYPERTENSIVE PATIENTS
by: Shuichi Ichikawa, et al.
Published: (2011-06-01)

Reversal of vascular hypertrophy in hypertensive patients through blockade of angiotensin II receptors
by: R. D. Smith, et al.
Published: (2010-12-01)

EFFECTS OF OLMESARTAN ON LOCAL AND REGIONAL RIGIDITY OF ARTERIES IN ISCHEMIC HEART DISEASE
by: I. B. Matrosova, et al.
Published: (2014-06-01)

PHARMACOECONOMIC ANALYSIS OF OLMESARTAN THERAPY IN THE INDIVIDUAL–LEVEL MANAGEMENT OF ARTERIAL HYPERTENSION
by: S. G. Gorokhova, et al.
Published: (2012-08-01)

Possibilities of nephroprotection in a comorbid patient with arterial hypertension
by: A. S. Skotnikov, et al.
Published: (2021-06-01)

EVALUATION OF ANTIHYPERTENSIVE THERAPY WITH THE COMBINATION OF OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE
by: Steven G. Chrysant, et al.
Published: (2011-06-01)

Angiotensin II type 1 receptor antagonists and ACE inhibitors in the regulation of hemodynamics and renin-angiotensin-aldosterone system activity: focus on the organ protection
by: M. L. Maksimov, et al.
Published: (2010-04-01)

A case report of olmesartan‐associated sprue‐like enteropathy: Diagnosis and healing confirmed by capsule endoscopy
by: Yoshiharu Yamaguchi, et al.
Published: (2023-04-01)

Combined treatment of arterial hypertension: focus on calcium antagonist and ACE inhibitor combination
by: V. I. Makolkin
Published: (2008-12-01)

The place of gliclazide MB in modern treatment strategies for patients with type 2 diabetes mellitus
by: N. A. Petunina, et al.
Published: (2024-09-01)

Nephroprotective strategy in the treatment of hypertension as a modern general medical problem
by: V. I. Podzolkov, et al.
Published: (2018-12-01)

PLACE OF ANGIOTENSIN II RECEPTOR ANTAGONISTS IN ARTERIAL HYPERTENSION THERAPY
by: S. A. Boytsov, et al.
Published: (2016-01-01)

Atypical Rapid Onset of Olmesartan-Induced Enteropathy with Recurrence After Rechallenging
by: Lila Bekkai, et al.
Published: (2025-07-01)

Arterial hypertension and Type 2 diabetes mellitus: any benefits for angiotensin II receptor blockers?
by: V. V. Fomin, et al.
Published: (2007-06-01)

Vasoprotection and nephroprotection: links of the same chain
by: N. Sh. Zagidullin, et al.
Published: (1970-01-01)

Angioprotection role in arterial hypertension treatment: focus on olmesartan
by: D. V. Nebieridze, et al.
Published: (2012-10-01)

КАРДИОНЕФРОПРОТЕКТИВНОЕ ДЕЙСТВИЕ СТАТИНОВ У БОЛЬНЫХ САХАРНЫМ ДИАБЕТОМ 2 ТИПА В СОЧЕТАНИИ С АРТЕРИАЛЬНОЙ ГИПЕРТОНИЕЙ
by: О. В. Боева, et al.
Published: (2013-10-01)

Correction of Endothelial Dysfunction in Patients with Essential Hypertension when Using a Combination of Olmesartan/Lercanidipine and Zofenopril/Lercanidipine
by: O. V. Zimnitskaya, et al.
Published: (2016-11-01)

ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN AND RAMIPRILIN ELDERLY PATIENTS WITH MILD TO MODERATE SYSTOLIC AND DIASTOLICESSENTIAL HYPERTENSION
by: J‑M. Mallion, et al.
Published: (2012-06-01)

PHARMACOECONOMIC STUDY OF OLMESARTAN/LERCANIDIPINE AND OFENOPRIL/LERCANIDIPINE COMBINATIONS IN THE TREATMENT OF PATIENTS WITH ESSENTIAL HYPERTENSION
by: D. S. Kaskaeva, et al.
Published: (2017-03-01)

Olmesartan‐Associated Enteropathy: An Uncommon Cause of Chronic Diarrhea
by: Ahmed Sayedahmed, et al.
Published: (2025-08-01)

ANTIHYPERTENSIVE EFFICACY AND SAFETY OF OLMESARTAN MEDOXOMIL AND RAMIPRIL IN ELDERLY PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION: THE ESPORT STUDY
by: E. Malacco, et al.
Published: (2012-02-01)

Acute vascular effects of the angiotensin II receptor antagonist olmesartan in normal subjects: relation to the renin-aldosterone system
by: L. M. Resnick, et al.
Published: (2011-12-01)

BLOOD PRESSURE-LOWERING EFFICACY OF OLMESARTAN RELATIVE TO OTHER ANGIOTENSIN II RECEPTOR ANTAGONISTS: AN OVERVIEW OF RANDOMIZED CONTROLLED STUDIES
by: Faiez Zannad, et al.
Published: (2010-08-01)

A Comparison Study of Olmesartan and Valsartan Effects on Myocardial Metabolism in Patients With Dilated Cardiomyopathy: the OVOID Trial
by: Sangyong Jo, et al.
Published: (2025-07-01)

Angiotensin II receptor antagonists – we have moved closer to the patient
by: L. G. Ratova, et al.
Published: (2005-04-01)

PROBLEMS IN PHARMACOTHERAPY OF RESISTANT ARTERIAL HYPERTENSION
by: N. V. Teplova, et al.
Published: (2013-12-01)

Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil
by: R. P. Mason
Published: (2012-06-01)

IRBESARTAN IN THE CLINICAL PRACTICE
by: V. I. Podzolkov, et al.
Published: (2015-09-01)

Cost-effectiveness analysis of nephroprotection programs for patients with type 2 diabetes mellitus in insurers in Colombia
by: Cristian Alejandro González-Rojas, et al.
Published: (2025-04-01)

The role of free radical oxidation in the kidneys in the nephroprotective action of eplerenone, a mineralocorticoid receptor antagonist, in experimental diabetes mellitus
by: A. Yu. Zharikov, et al.
Published: (2021-07-01)

Nephroprotective peptides of Laennec® in the context of pharmacotherapy for nephro-hepato-metabolic disorders
by: O. A. Gromova, et al.
Published: (2024-02-01)